Expansion through acquisitions USV is actively expanding its portfolio through strategic acquisitions, including a 79% stake in Wellbeing Nutrition for approximately $188 million, signaling a pivot toward high-growth weight management and clinical nutrition markets. This presents cross-selling opportunities to integrate Wellbeing Nutrition’s D2C reach with USV’s existing pharmaceutical and consumer health channels.

Premium product roadmap With launches such as usema in the semaglutide space and empagliflozin combinations for diabetes care, USV is strengthening its leadership in cardiometabolic therapies. This creates sales potential for allied products, formulations, and complementary devices or services in clinics and pharmacies targeting diabetes and cardiovascular risk management.

Global manufacturing footprint USV operates seven manufacturing plants across India with USFDA, EMA, MHRA and other accreditations, enabling reliable supply for international markets. This capability supports regional expansion, contract manufacturing for partners, and timely global distribution for new products and co-branded initiatives.

D2C and consumer leverage The consumer business through Sebamed and wellness brands positions USV to scale direct-to-consumer initiatives and cross-sell pharmaceutical-grade nutrition and dermatology products. There are opportunities to expand online channels, digital marketing, and subscription models in health and wellness segments.

Strategic partnerships USV’s United for BP Control initiative and collaborations with WHL and the Indian Society of Hypertension demonstrate a commitment to public health programs. This opens doors for partnership-based campaigns, sponsorships, and B2B collaborations with hospitals, clinics, and payer programs to drive volume in hypertension, diabetes, and related therapies.